Stock Detail
IMMUNOGEN INC
Drugs
IMGN @ Yahoo Finance | IMGN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $12.19 | $12.95 | $-0.26 | -2.09% | 0.00 | $12.45 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $12.28 | $12.16 | 421,858 | 931.75M | 736,122.67 | -13.25 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 13.22 | 12.70 | 12.43 | 11.91 | 11.64 |
Stock Profile
ImmunoGen, Inc. engages in the discovery and development of therapeutic monoclonal antibodies and treatments in the field of oncology in the United States and the United Kingdom. It develops novel, targeted therapeutics using its tumor-activated prodrug (TAP) technology, which uses monoclonal antibodies to deliver potent cell-killing agents. The company's two leading product candidates include huN901-DM1 and huC242-DM4, which are in clinical testing stage. Its huN901-DM1 product candidate consists of the huN901 antibody, which binds to the CD56 antigen, a cytotoxic agent. The company's second clinical TAP product candidate, huC242-DM4, consists of the humanized C242 monoclonal antibody with its cytotoxic agent attached and is in development for the treatment of colorectal, pancreatic, and other cancers. ImmunoGen also licenses its TAP technology to other biotechnology and pharmaceutical companies. ImmunoGen has collaborative partnerships with sanofi-aventis, Biogen Idec, Inc.; Boehringer Ingelheim International GmbH; Centocor, Inc.; Millennium Pharmaceuticals, Inc.; Abgenix, Inc.; Genentech, Inc.; and GlaxoSmithKline plc. The company was organized in 1981 and is headquartered in Cambridge, Massachusetts.